Skip to main content
padlock icon - secure page this page is secure

Pomalidomide‐dexamethasone for treatment of soft‐tissue plasmacytomas in patients with relapsed / refractory multiple myeloma

Buy Article:

$52.00 + tax (Refund Policy)

The presence of plasmacytomas (Ps) in patients with multiple myeloma (MM) is associated with a poor outcome, both in patients treated conventionally and in patients treated with novel agents. Two types of plasmacytomas have being recognized: paraskeletal plasmacytomas (PPs) and extramedullary plasmacytomas (EMPs), being the incidence of EMPs lower but with worse prognosis. Our aim has been to analyze the efficacy of the pomalidomide‐dexamethasone combination in this patient profile.
No References
No Citations
No Supplementary Data
No Article Media
No Metrics

Keywords: multiple myeloma; plasmacytomas; pomalidomide

Document Type: Research Article

Publication date: May 1, 2019

  • Access Key
  • Free content
  • Partial Free content
  • New content
  • Open access content
  • Partial Open access content
  • Subscribed content
  • Partial Subscribed content
  • Free trial content
Cookie Policy
X
Cookie Policy
Ingenta Connect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more